Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Stock Information for Lisata Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lisata Therapeutics Inc.

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.